Validation of a Gene Expression Signature to Measure Immune Quiescence in Kidney Transplant Recipients in the CLIA Setting

Rocky Cheung,Hua Xu,Xia Jin,Wenlan Tian,Kevin Pinney,Lihong Bu,Steven Stone,Robert N. Woodward,Nikhil Agrawal,Shamik Dholakia,Ryan T. Phan
DOI: https://doi.org/10.2217/bmm-2022-0113
2022-01-01
Biomarkers in Medicine
Abstract:Aim: Allograft rejection remains a major cause of graft failure in kidney transplantation. Here the authors report the validation of a non-invasive molecular diagnostic assay, AlloMap Kidney, using peripheral blood. Methods: The AlloMap Kidney test is a gene expression profile utilizing the RNA-seq platform to measure immune quiescence in kidney transplant patients. Results/Conclusions: Analytical validation showed robust performance characteristics with an accuracy correlation coefficient of 0.997 and a precision coefficient of variation of 0.049 across testing. Clinical validation from the prospective, multi-center studies of 235 samples (66 rejection and 169 quiescence specimens) demonstrated the sensitivity of 70% and specificity of 66% for allograft rejection, while the negative predictive value was 95% to discriminate rejection from quiescence at 10% prevalence of rejection.
What problem does this paper attempt to address?